Roivant Sciences, Inc.
101 articles with Roivant Sciences, Inc.
-
Roivant Licenses Splicing Modulator and Announces Upcoming Presentation at 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
Roivant Sciences (Nasdaq: ROIV), today announced that it has entered into a licensing agreement with Eisai Co., Ltd. for exclusive global rights to the investigational agent RVT-2001 (also known as H3B-8800), which will provide the lead program for a new subsidiary Vant.
-
Roivant Sciences Reports Financial Results for the Quarter Ended September 30, 2021 and Provides Business Update
11/15/2021
Roivant Sciences Ltd., a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, reported its financial results for the second fiscal quarter ended September 30, 2021 and provided an update on the Company’s operations.
-
Roivant to Report Financial Results for the Quarter Ended September 30, 2021 on Monday, November 15, 2021
11/8/2021
Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 15, 2021 to report its second quarter 2021 financial results and provide a corporate update.
-
Roivant Discovery Announces 2021 Open Science Fellows
10/29/2021
Drs. Gregory Bowman, Alex Dickson and Paul Robustelli selected as fellows due to shared focus on understanding the structures and dynamics of biological systems at atomic resolution
-
The incidence of congenital athymia is about 17 to 24 lives births each year in the U.S. The therapy is a one-time regenerative tissue-based therapy.
-
Roivant Sciences Announces Close of Business Combination with Montes Archimedes Acquisition Corp. and Concurrent PIPE Financing
10/1/2021
Roivant Sciences, a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced that it has closed its business combination with Montes Archimedes Acquisition Corp., a special purpose acquisition company, as well as a concurrent PIPE financing.
-
Jose Luis Casero Sanchez took advantage of his position in Goldman Sachs’ “control room” to gain insider knowledge of upcoming transactions, including those for several biopharma companies.
-
Roivant Sciences Reports First Fiscal Quarter 2021 Financial Results and Provides Business Update
9/21/2021
- Roivant on track to close business combination with Montes Archimedes Acquisition Corp. and concurrent PIPE financing, and commence trading on Nasdaq on October 1 under the symbol
-
Roivant Provides Corporate Updates
6/9/2021
Datavant and Ciox Health have signed a definitive merger agreement - Combined company positioned to solve the challenge of health data fragmentation.
-
The $7 billion transaction by Datavant with Ciox Health will be the nation's largest "neutral and secure health data ecosystem."
-
Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology
5/3/2021
- Transaction includes $411 million in trust at MAAC and a concurrent, fully committed $200 million PIPE financing from leading healthcare investors including Fidelity Management & Research Company LLC, Eventide Asset Management, Suvretta Capital, RTW Investments, LP, Viking Global Investors, and SB Management, a subsidiary of SoftBank Group Corp., as well as strategic investors including Sumitomo Dainippon Pharma and Palantir Technologies
-
Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC). Once the deal is closed, outstanding shares and warrants of MAAC will be traded for newly issued shares and warrants of the company.
-
Enzyvant has resubmitted its Biologics Licensing Application to the U.S. FDA for its tissue-based regenerative pediatric congenital athymia therapy RVT-802.
-
Roivant Grows Computational Drug Discovery Engine with Acquisition of Silicon Therapeutics
2/26/2021
Leading computational physics-based platform for design and optimization of small molecules bolsters Roivant's drug discovery capabilities
-
The Silicon Therapeutics acquisition is designed to complement Roivant’s targeted protein degradation platform.
-
Its potential remittive effects could hold even more value for long-term psoriasis suffers. For patients coming into the trial with a PGA score of 0 (n=78), median time to the disease worsening (defined as a PGA score of ≥2) after discontinuing treatment was approximately 115 days, or 4 months.
-
If you know Roivant as a brand you might be familiar with Vivek Ramaswamy too. Recently, he stepped down as CEO and became Executive Chairman. Let's know more.
-
Roivant Sciences to Present at 39th Annual J.P. Morgan Healthcare Conference
1/8/2021
Recent milestones include first two FDA approvals at Vants launched by Roivant, positive clinical data at Dermavant, Aruvant, and Immunovant, and multiple computationally-designed protein degraders advanced into preclinical development
-
Roivant Unveils Targeted Protein Degradation Platform
12/7/2020
Acquisition of Oncopia Therapeutics and research collaboration with lab of Dr. Shaomeng Wang at the University of Michigan to add diverse pipeline of current and future compounds
-
Roivant Announces Protein Degradation Platform Using VantAI Against Difficult Drug Targets
12/7/2020
Roivant Sciences announced its targeted protein degradation platform, with its first pipeline candidate expected to enter the clinic in 2021.